A Phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy

A Phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy. The main objective of this study is to see if riliprubart works to improve your disease symptoms and their impact on your daily activities. Overall, the study will last approximately 109 weeks and will include up to 160 study participants worldwide.